论文部分内容阅读
膀胱内卡介苗(BCG)治疗浅表移行细胞癌及原位癌疗效显著,这已被广泛证实。但很少有人提倡将BCG治疗用于膀胱切除的病人,争论的焦点在于BCG治疗能否诱发全身性肿瘤特异反应,或者能否对肿瘤不仅局限于膀胱粘膜的病人产生作用。本研究的目的在于确定膀胱纤维粘连蛋白(FN)的表达水平与BCG治疗浸润性膀胱移行细胞癌的关系。13例膀胱肿瘤病人,年龄50～78岁,其中T2期8例,T3期2例,T4期3例。切除原
Intravesical BCG treatment of superficial transitional cell carcinoma and carcinoma in situ significant effect, which has been widely confirmed. However, few people advocate the use of BCG for cystectomy. The focus of the debate is whether BCG treatment can induce a systemic tumor-specific response or whether it can affect patients with tumors that are not limited to the bladder mucosa. The purpose of this study was to determine the relationship between the expression of bladder fibronectin (FN) and BCG for invasive bladder transitional cell carcinoma. 13 cases of bladder cancer patients, aged 50 to 78 years, of which 8 cases of T2, T3 in 2 cases, T4 in 3 cases. Excise the original